Chronic myeloid leukaemia is a slowly developing blood cancer that affects the bone marrow and blood cells, causing the body to produce too many abnormal white blood cells. While this diagnosis can feel overwhelming, modern treatments have transformed it from a life-threatening condition into a manageable chronic illness for many patients.

Understanding the Goals of Treatment

The main goal when treating chronic myeloid leukaemia, often called CML, is to achieve and maintain what doctors call remission, which means there are no detectable signs of leukaemia in the blood and bone marrow. Unlike cancers that might be completely eliminated with treatment, CML usually remains in the body but can be controlled effectively with ongoing medication. The focus is on controlling the disease, preventing it from progressing to more aggressive stages, and allowing patients to maintain a good quality of life with minimal symptoms.^[1]

Treatment choices depend heavily on the phase of the disease when it is discovered. Most people are diagnosed during what is called the chronic phase, when the disease develops slowly and may not cause noticeable symptoms. This is the most treatable stage. Some people, however, are diagnosed in the accelerated or blast phase, where the disease has progressed further and requires more intensive treatment. Your age, overall health, whether you have other medical conditions, and how you respond to initial treatment all play important roles in determining which therapies will work best for you.^[2]

Medical guidelines from cancer organizations and health authorities recommend specific approaches based on decades of research and clinical experience. At the same time, researchers worldwide are continuously testing promising new therapies in clinical trials, hoping to improve outcomes even further and offer options for patients whose disease doesn’t respond well to standard treatments.

Standard Treatment Options

The standard treatment for chronic myeloid leukaemia has been revolutionized by a class of medications called tyrosine kinase inhibitors, or TKIs. These are targeted cancer drugs that work very differently from traditional chemotherapy. Rather than attacking all rapidly dividing cells, TKIs specifically block the abnormal protein created by the genetic change that causes CML.^[3]

To understand how these drugs work, it helps to know what happens in CML at the cellular level. People with this leukaemia have a genetic abnormality called the Philadelphia chromosome, which occurs when pieces of two chromosomes swap places. This creates a new fused gene called BCR-ABL, which produces an abnormal tyrosine kinase enzyme that tells bone marrow stem cells to divide uncontrollably. TKI drugs act like an “off switch” for this abnormal enzyme, stopping the excessive production of abnormal white blood cells.^[1]

The most commonly used TKI is imatinib, which was the first of these drugs to be approved and has been used successfully for many years. Other TKIs include bosutinib, dasatinib, and nilotinib. These medications are taken as pills, usually once or twice daily, making them relatively convenient compared to treatments that require hospital visits or intravenous infusions.^[4]

Doctors choose which TKI to start with based on several factors, including the phase of your disease, your risk category, and any other health conditions you might have. For most people diagnosed in the chronic phase, treatment begins with one of these oral medications. The goal is to achieve specific responses at certain time points. Within three months, your blood counts should return to normal in what’s called a complete hematologic response. Over the following months and years, the amount of BCR-ABL in your blood should continue to decrease, measured through regular blood tests.^[5]

Like all medications, TKIs can cause side effects, though not everyone experiences them, and many side effects can be managed effectively. Common side effects include nausea, diarrhea, muscle cramps, fatigue, and fluid retention that can cause swelling. Some people develop skin rashes or experience changes in their blood counts. More serious but less common side effects can include problems with heart function or lung inflammation. Different TKIs have different side effect profiles, so if one drug causes intolerable side effects, switching to another TKI may help.^[2]

Regular monitoring is essential during treatment. You will need blood tests every few weeks initially, then less frequently as your disease comes under control. A test called polymerase chain reaction, or PCR, measures the amount of BCR-ABL gene material in your blood, helping doctors assess how well treatment is working. Bone marrow tests may also be needed occasionally to check the status of your disease more directly.^[6]

For people who don’t respond well to TKIs or whose disease progresses despite treatment, other options may be considered. Traditional chemotherapy uses drugs that kill rapidly dividing cells throughout the body. While less commonly needed now than in the past, chemotherapy may be used in advanced phases of CML or to prepare the body for a stem cell transplant.^[7]

Stem cell transplantation, also called bone marrow transplant, involves replacing diseased bone marrow with healthy stem cells from a donor. This is an intensive treatment with significant risks and is usually reserved for people with advanced disease that hasn’t responded to multiple TKIs, or for younger patients who have a suitable donor. Before the transplant, patients receive high doses of chemotherapy and sometimes radiation to destroy the leukaemia cells and make room for the new stem cells. The donor stem cells are then infused into the bloodstream and travel to the bone marrow, where they begin producing healthy blood cells.^[4]

Innovative Treatments in Clinical Trials

While TKIs have dramatically improved outcomes for people with CML, researchers are working to develop even better therapies. Clinical trials are research studies that test new treatments or new combinations of existing treatments to see if they are safe and effective. These trials are conducted in phases, each with a specific purpose.

Phase I trials primarily test safety and determine the appropriate dose of a new treatment. They typically involve small numbers of patients and focus on understanding how the drug affects the human body and what side effects it might cause. Phase II trials expand to more patients and begin evaluating whether the treatment actually works against the disease, while continuing to monitor for side effects. Phase III trials compare the new treatment against current standard treatments to see if it offers advantages, and they involve larger numbers of patients at multiple locations.^[5]

One area of research focuses on developing newer generations of tyrosine kinase inhibitors that might work better or cause fewer side effects than current options. Some experimental TKIs are designed to work against CML cells that have become resistant to existing drugs. When CML cells develop resistance, it’s often because the BCR-ABL protein has mutated in ways that prevent current TKIs from binding to it effectively. Newer drugs are being designed to overcome these resistance mutations.^[9]

Another promising avenue of research involves trying to eliminate the CML stem cells that persist even when the disease appears well-controlled. These residual stem cells are thought to be responsible for disease relapse when treatment is stopped. Researchers are testing various approaches to target these persistent cells, including combining TKIs with other types of drugs that work through different mechanisms.^[3]

Immunotherapy represents an exciting frontier in cancer treatment, and researchers are exploring its potential for CML. This approach harnesses the body’s own immune system to recognize and attack cancer cells. Some studies are testing whether immune-based therapies could help patients achieve deeper remissions or potentially allow them to stop TKI treatment safely. These therapies might work by teaching immune cells to better recognize and destroy CML cells, or by removing the brakes that prevent the immune system from attacking cancer.^[12]

Clinical trials for CML are conducted in many countries, including the United States, throughout Europe, and in other regions worldwide. Eligibility for specific trials depends on many factors, including the phase of your disease, which treatments you’ve already received, your overall health status, and the specific requirements of each study. Some trials specifically recruit people with newly diagnosed CML, while others focus on those whose disease has progressed or hasn’t responded adequately to standard TKIs.^[5]

Participating in a clinical trial can provide access to promising new treatments before they become widely available. However, clinical trials also involve uncertainties. A new treatment being tested might not work as well as standard options, or it might cause unexpected side effects. Trial participants usually require more frequent monitoring and testing than those on standard treatment, which can mean more clinic visits and procedures. The decision to join a clinical trial is personal and should be made after thorough discussion with your healthcare team about the potential benefits and risks.^[3]

Some research is investigating whether combining TKIs with other types of medications might improve outcomes. For example, studies have tested adding drugs that affect different cellular pathways involved in cancer growth. Other trials explore optimal timing for starting or stopping treatment, or whether certain patients might benefit from higher or lower doses of medications than are typically prescribed.^[12]

Early results from some ongoing trials have shown promise. Certain newer TKI drugs have demonstrated good safety profiles while effectively controlling CML in patients who hadn’t responded well to earlier treatments. Some combination approaches have shown the potential to achieve deeper molecular responses, meaning even lower levels of detectable leukaemia cells. However, it’s important to remember that preliminary trial results need to be confirmed in larger studies before these approaches become standard practice.^[15]

Most common treatment methods

• Targeted therapy with tyrosine kinase inhibitors (TKIs)
  • Imatinib – the first TKI approved for CML, taken as daily pills
  • Dasatinib – an alternative TKI that may be used if imatinib doesn’t work well
  • Nilotinib – another TKI option for chronic phase CML
  • Bosutinib – a TKI used for patients who haven’t responded to other treatments
  • These drugs specifically block the abnormal BCR-ABL protein that drives CML
  • Work by acting like an “off switch” for uncontrolled cell growth
• Chemotherapy
  • Uses drugs like fludarabine, cytarabine, and idarubicin to kill rapidly dividing cells
  • May be combined with TKI drugs in advanced disease stages
  • Often used to prepare patients for stem cell transplantation
  • Less commonly needed now than before TKIs became available
• Stem cell transplantation
  • Involves replacing diseased bone marrow with healthy donor stem cells
  • Requires intensive chemotherapy preparation before the transplant
  • Reserved for advanced disease or patients who don’t respond to multiple TKIs
  • Offers potential for long-term disease control but carries significant risks
• Experimental treatments in clinical trials
  • Newer generation TKIs designed to overcome drug resistance
  • Combination therapies pairing TKIs with other types of drugs
  • Immunotherapy approaches to activate the immune system against CML cells
  • Treatments targeting persistent CML stem cells

Managing Life with CML

Living with chronic myeloid leukaemia means adapting to a new reality where regular medical care and daily medication become part of your routine. Many people find that once their disease is well-controlled with treatment, they can return to most of their normal activities, including work, hobbies, and social life. However, it’s also common to experience ongoing concerns about the future and to deal with treatment side effects that can affect daily life.^[17]

Fatigue is one of the most common challenges people with CML face, both from the disease itself and as a side effect of treatment. This isn’t ordinary tiredness but a profound exhaustion that doesn’t improve with rest. Research suggests that gentle regular exercise, such as walking, can actually help manage fatigue, though it’s important to pace yourself and not overdo activities. Working with your healthcare team to address fatigue might involve adjusting medication timing, treating related conditions like anemia, or connecting with supportive care services.^[19]

Regular follow-up care is essential for monitoring how well treatment is working and catching any problems early. Initially, you’ll need frequent blood tests to check your response to treatment. As the disease comes under better control, these appointments typically become less frequent, though you’ll likely need ongoing monitoring for as long as you have CML. These visits are also opportunities to discuss any symptoms, side effects, or concerns with your medical team.^[18]

Emotional and psychological support can be just as important as medical treatment. Learning you have cancer, even a treatable form like CML, can trigger powerful feelings including shock, fear, anger, or sadness. These emotional responses are completely normal. Some people find it helpful to talk with a counselor or therapist who understands cancer-related concerns. Support groups, whether in-person or online, allow you to connect with others facing similar challenges. Many cancer centers offer these services, and there are also independent organizations dedicated to supporting people with blood cancers.^[17]

Practical matters like work and finances often need attention. Some people can continue working throughout treatment with minimal disruption, while others need to take time off or adjust their work schedule. Fatigue and the need for frequent medical appointments can make maintaining regular work hours challenging. It’s worth discussing your situation with your employer and learning about any available accommodations or leave policies. Financial concerns about treatment costs and potential lost income are common, and social workers or patient navigators at your treatment center may be able to help connect you with resources.^[17]

Maintaining overall health through good nutrition, regular physical activity within your capabilities, and adequate rest can support your body during treatment. Some TKI medications can increase sensitivity to sunlight, making sun protection especially important. Staying hydrated and eating a balanced diet can help manage some treatment side effects, though severe nausea or other symptoms should be discussed with your doctor as there may be medications or strategies to help.^[19]